Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Ambroxol Lozenges in Healthy Males
NCT02194283Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2009
- Primary completion
- Nov 2009
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial in bronchopulmonary diseases comparing Ambroxol with Placebo (2 arms). Primary endpoints: Maximum measured concentration of the analyte in plasma up to 24 hours, Time from dosing to the maximum concentration up to 24 hours and 13 more. Started Oct 2009; status: completed.
02
Drugs
ambroxol
03
Conditions
bronchopulmonary diseases
Beyond the preview
Go deeper on NCT02194283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02194283.